Free Trial
NASDAQ:SNTI

Senti Biosciences Q4 2023 Earnings Report

Senti Biosciences logo
$1.54 -0.15 (-8.88%)
Closing price 04:00 PM Eastern
Extended Trading
$1.58 +0.04 (+2.92%)
As of 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Senti Biosciences EPS Results

Actual EPS
-$4.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Senti Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Senti Biosciences Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Thursday, March 21, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Senti Biosciences' Q3 2025 earnings is scheduled for Thursday, August 7, 2025

Senti Biosciences Earnings Headlines

One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
See More Senti Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Senti Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Senti Biosciences and other key companies, straight to your email.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

View Senti Biosciences Profile

More Earnings Resources from MarketBeat